<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 320 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page319.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=320">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 320 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 320</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=320"><img src="../thumb/320.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Anti-Microbials - 18.12                                                        2020-04 / 283
       Indications: In combinat.with other antiretrovir. in adults with HIV-  VALCYTE, Roche [P/S]  Warnings: Thrombot./thrombocytopen.purpura/ haemolyt. uraem.
       1 infect., with safer sex practices for pre-expos.prophylax.(PrEP).in   Valganciclovir  syndr poss.result.in death report. in pts.with advanc.HIV dis./aft.
       confirm. HIV-1 uninfect.adults to reduc.risk of sex. acquir.HIV-1 in at   Indications: Treatm.of CMV retinit.in AIDS pts., prevent.of CMV   bone marr.& ren. transpl.
       risk adults prov.max. treatm. compliance monitor.  dis.in solid organ transplant pts.at risk.  Drug interactions: Cimetidine & probenec.decr. ren.excret., plasma
       (S4) TABS, 44/20.2.8/0086     (S4) TABS, 37/20.2.8/0296    AUC’s of aciclovir & mycophenolate both incr.when admin.concom.
       715071-001: 30, R477,04       703908-001: 450 mg, 60, R29 946,81
       Dosage: HIV infect: 1 tab.once dly.without regard to food.  (S4) POWD.FOR ORAL SOL, 43/20.2.8/0433  VIREAD, (Aspen Pharmacare: Pharma)
       PrEP: 1 tab.once dly.without regard to food.  719358-001: 50 mg/ml, 100 ml, R5 240,70  Pharmacare [P/S]
       Contraindications: Safety & effic.not est.in hepatit.B vir.& HIV   Dosage: Admin.with food. To avoid overdos. adhere strictly to   Tenofovir disoproxil fumarate
       co-infects., creatin.Cl &lt;60 ml/ min.when used for HIV PrEP, crea-  dosage recommendat. Syst. expos. follow.900 mg oral sol.is equiv.  Indications: In combinat.with other antiretrovir.in adults with HIV-
       tin.Cl &lt;50 ml/ min.when used for HIV-1 treatm., pregn.& lactat.,   to 900 mg tab.dos.  1., monother. in HIV uninfect. adults. for treatm.of chron.hepatit.B
       concom.lamivudine/tenofovir or emtricitabine contain.prod. PrEP   Adults:  with compensat. liv. dis./evid.of act.viral replicat./ persist. elev.ALT
       use in pts with unknown/ posit. HIV-1 status/pts.not commit.to   CMV retinitis: Induct.treatm with act.CMV retinitis: 900 mg   & histologic.evid.of act. inflam. &/ fibros.
       treatm. compliance,           2xdly x21 days. Prolong.treatm. may incr.bone marr.toxic.risk.  (S4) TABS, A40/20.2.8/0681
       Side effects: Lactic.acidos.& sev.hepatomegaly with steatos.incl.  Maint.treatm.follow.induct.treatm./in inact. CMV retinitis:   708253-001: 300 mg, 30, R407,49
       fatal., sev.ac.exacerbat.of hepatit. B aft.discontinuat., inflamm.re-  900 mg once dly. Induct.treatm.may be rep.in pts.where retinitis   Dosage: 300 mg once dly.without regard to food.
       spons.to indolent/resid.infects., anaem., neutropen., allerg. react.  worsens but consid. poss. vir.drug resist.  Contraindications: Safety & effic.not est.in hepatit. B vir.co-in-
       incl.angioed., hyperglycaem., hypertriglyceridaem., hypophospha-  CMV prophylax in solid organ transplantat: Kidn.transpl.  fects., any degree ren.fail., pregn. & lactat., safety & effic.in childr.
       taem., lact. acidos., hypokalaem., insomn., abnorm.dreams, depress.,   pts.: 900 mg once dly.dep.on creatin. clear. start.within 10 days of   und.18 yrs./ &lt;35 kg.with chron. HBV.not est., in treatm. of chron.
       dizzin., headache, neurit., paraesthes., periph. neuropathy, dyspn.,   transplant until 200 days post transplantat. Pts.receiv.solid org.   HBV: concom.adefovir dipivoxil.
       incr.cough, rhinit., abdom./back/chest pain, pneumon., GI disturbs.,   transpl. other than kidn.: 900 mg once dly. start. within 10 days   Side effects: Lactic.acidos.& sev.hepatomegaly with steatos.incl.
       rais. liv.enzymes, pancreatit., hyperbilirubinaem., hepatit., hepat.  of transplant until 100 days post transplantat.  fatal., pot.fatal lactic acidos. as conseq. of mitochondr. dysfunct.,
       steatos., rash, skin discolourat., hyperpigmentat., myopathy, osteo-  Contraindications: Ganciclovir hypersens., not recomm.in childr./  sev.ac.exacerbat. of hepatit. B aft.discont., ren.impairm.incl.ac.ren.
       malac., rhabdomyolys., musc. weakn., ren.insuffic./-fail., ac.ren.  haemodialys.pts., safety in pregn. & lactat.not est., safety & effic.in   fail., mild to mod.GI effs., dizzin., headache, pain, fev., abdom./
       fail.& Fanconi syndr., nephrogen.diab. insipid., pain, asthen., fev.,   elderly & paed.pts.not est.  back/chest pain, asthen., lipodystrophy, arthralg., myalg., depress.,
       sweat., weight loss, arthralg., myalg., anorex., haematur., body fat   Side effects: Leucopen./neutropen./anaem./ thrombocytopen./  insomn., periph. neuropathy, anx., pneumon., rash, sweat., weight
       redistribut./accumulat.,      pancytopen./bone marr. depress. & aplast.anaem., GI disturbs.,oral   loss, allerg.reacts., hypophosphataem., hypokalem. dyspn., pan-
       Warnings and special precautions: Monit. hepat. funct.for sev.   candidias., sepsis, cellulit., UTI, anaphylact.react., psych.& psy-  creatit., incr.liv.enzymes, hepatit., BMD decr.from baseline, fat re-
       mnths.if discont.& pts.co-infect. with HIV & HBV, only admin.for pre-  chot.disords., headache, insomn., dysgeus., hypoaesthes., par-  distribut., inflamm.respons.to indolent/resid.infects. necessit. furth.
       expos. prophpylax.(PrEP) to pts.confirm as HIV negat.init. & every 3   aesthes., periph.neuropathy, dizzin., convuls., trem., vis.disturbs.  eval.& treatm., osteonecros., Fanconi syndr., myopathy, osteomalac.,
       mnths.dur.use as resist.HIV-1 variants. identif follow.PrEP treatm.in   incl.macul. oed. & retin.detachm., ear pain, deafn., dysrhythm.,   rhabdomyolys., musc.weakn.
       undetect.ac.HIV-1 infect., no stud.demonstrat.eff.on clinic. progress.   hypotens., dyspn., cough, sev.hepat.funct. abnormal., dermatit.,   Warnings and special precautions: Pts.treat. for hepatit. B in-
       of HIV-1, not recomm.as part of triple nucleoside regim., advis.PrEP   night sweats, prurit., alopec., urticar., dry skin, back pain, arthralg.,   fect.should be prov.to be HIV neg. & reg. test.for HIV infect., eff.on
       pts.that full compliance & addit.prevent.meas.essent., obesity & pro-  myalg., musc. cramps., ren.impairm./fail., male infertil., malaise,   clinic.progress.of HIV-1 not demonstrat., obesity & prolong. nucleo-
       long.nucleoside use poss.risk fact. for lact.acidos., liv.dis.risk fact.,   pyrex., pain, chest pain, decr.weight., Paed pts also: hypertens.,   side use poss.risk fact.for lact.acidos., liv. dis. risk fact., discont.if find.
       discont.if find. suggest. lact.acidos./hepatotoxic., safety & effic. not   URTI, transpl.reject.  suggest.lact.acidos./ hepatotoxic., imp.ren.funct., pts.at risk of ren.
       est.in signific.underly.liv.disords./dis., incr. freq. of liv.funct.abnormal.  Warnings and special precautions: Aciclovir & valaciclovir   dysfunct., persist./worsen.bone pain/pain in extremit./ fract.&/musc.
       in pre-exist.liv. condits. theref.monit.& poss.discont.if evid of worsen.  cross-hypersens., effect.contracept. for women of child bear.potent.  pain or weakn.poss. manifest. of proxim.ren.tubulopathy & should
       liv.dis.pres., investig.infts./childr.expos in utero for poss.mitochon-  dur.treatm.& men to pract. barrier contracept.dur.treatm.& for at least   prompt ren.funct.eval.in pts.at risk, concom./rec. nephrotox. meds.,
       drial dysfunct. in case of relev.signs & sympts., test for chron.hep-  90 days follow.treatm., ther.not to be init.if absol. neutrophil count   adjust.dos.interv.if creatinine clear. &lt;50 ml/L, test for hepatit.B bef.
       atit. B virus bef.init.ther., refer to HIV treatm.guidelines/ relev.PI’s in   &lt;500 cells/µl, if platelet count &lt;25 000/µl or Hb &lt;8 g/dL, monit.full   init.ther., discont. concom.didanosine if didanosine advers. effs. de-
       case of concom.hepat.B or C, monit. hepat.funct.in co-infect.HIV &   bld.& platelet counts dur.ther., consid.haematopoiet.growth fact.   velop, recom.concom.atazanavir be admin. with ritonavir, monit.BMD
       HBV pts,init.anti-hepatit.B ther.if warrant., imp.ren.funct., concom./   treatm.and/or dos.interrupt.in sev.leucopen./ neutropen./anaem.&/  in pts.with patholog. bone fract.hist./at risk of osteopen., Ca & vit.D
       rec.nephrotox.meds., recom.concom. atazanavir be admin.with rito-  thrombocytopen., bioavailabil. is up to 10-fold high.than from gan-  supplementat. poss benefic., pts.with evid.of lipodystrophy should
       navir, concom. didanosine to be und.fast.condits./monit.& discont.   ciclovir caps., cannot be substit.on 1:1 basis with ganciclovir caps.,   have thorough CV risk assessm., immune reconstitut.inflam.syndr.,
       if advers.effs.develop,monit.BMD in pts. with patholog.bone fract.  imp.ren.funct., avoid concom. imipenem-cilastatin unless benefit out-  investig. childr.expos.in utero to nucleoside & nucleotide analog.for
       hist./at risk of osteopen., pts.to report joint S/E’s & diffic in movem.,   weigh. risk as seiz.report., monit. for didanosine toxic., concom.zido-  poss.mitochondr.dysfunct.in case of relev.S&S, contin.approp.pre-
       CV risk assessm.in pres.of lipodystrophy, reg.vir.load monit.& CD4   vudine & ganciclovir ther.at full dos. poss.not tolerat.as both agents   caut.prevent. HIV transmiss.risk, discont.use if pancreatit. suspect.,
       counts recomm., concom.treatm.does not reduc. risk of HIV trans-  monit.vir.load/CD4 count reg., contains lactose
       miss., safety & effic.in paed.pts.not est., elderly, galactosaem/gluc./  have neutropen. & anaem.caus.potent., monit.for periph neuropathy   Drug interactions: Ser.conc.of drugs elimin.by act.tubul.secret.may
                                     with concom zalcitabine, teratogen.& embryotox. in anim. studies,
       galact. malabsorpt. syndr.                                 incr., ser.conc.incr.by agents decr.ren.funct., C max & AUC of didanosine
       Drug interactions: Cmax & AUC of didanosine incr., conc.incr.with   ren.impairm., haemodialys., mild skin/eye & muc.membr.irrit. with   incr., AUC & C min of atazanavir decr., incr.conc.with concom. ataza-
       atazanavir & lopinavir/ ritonavir, AUC & C min of atazanavir decr., conc.   oral sol., handle powd.for oral sol & reconstit. Sol. with care &   navir & lopinavir/ritonavir
       incr. with concom.drugs reduc.ren.funct./ elimin. by act.tubul.secret.,   throughly wash area immed.if it comes in contact with skin/in eyes.  VIREF, Emcure [P/S]
       abacavir C max incr., C max of indinavir & lamivudine decr.with tenofovir.  Drug interactions: Didanosine plasma conc.incr., enhanc.toxic.with
                                     myelosuppress.meds.& drugs assoc. with ren.impairm., probenec.  Efavirenz.
       VALATREX, (Unicorn) Sandoz [P/S]  reduc.ren. clear., zidovudine’s AUC may incr.& ganciclovir’s AUC may   Indications: In combinat.with other antiretrovir. agents for HIV-1
       Valaciclovir                  decr.when given concom., concom. mycophenolate incr.conc.of both   infect.adults, adolesc.& childr. weigh.40 kg and above.
       Indications: Herpes zoster (shingles) reduc. zoster-assoc.pain, re-  meds., Zalcitabine incr. AUC0-8h of oral ganciclovir  (S4) TABS, 43/20.2.8/0580
       curr.genit.herpes.in immunocompet.adult pts., prevent./suppress.of   718099-001: 600 mg, 30, R203,92
       recurr. H.simplex infect.of skin & ano-genit. mucous membr., CMV   VAVIREX, (Pharmacare) Aspen Pharmacare [P/S]  Dosage: Admin.in combinat.with a protease inhibit. &/ NRTI’s. Take
       infect.prophylax., CMV dis. & other herpes vir.infect.prophylax.aft.  Valaciclovir  on empty stomach pref.at bedt. dur.1  2-4 wks to improve CNS effs
                                                                                  st
       organ transpl. in spec.risk cases.  Indications: Herpes zoster (shingles), recurr. genit. herpes.in immu-  toler. Use only in adults & childr.weigh.great.than or equal to 40 kg
       (S4) TABS. 42/20.2.8/0341     nocompetent adult pts., prevent.of recurr.H.simplex infect.of skin &   Adults: 600 mg once dly. Adolesc.& childr.(17 yrs.& und):
       721152-002: 500 mg, 10, R189,07  ano-genit.mucous membr., CMV infect.prophylax., CMV dis.& other   600 mg at bedt.
       721152-003: 500 mg, 30, R567,33  Herpes vir.infect.prophylax. +aft.organ transplant.  Contraindications: Concom.astemizole/ cisapride /midazolam/tri-
       721152-001: 500 mg, 42, R794,29  (S4) TABS. 43/20.2.8/0388  azolam/ergot derivat., childr. weigh.less than 40 kg, not recomm.dur.
       Dosage: Treatm.to start as soon as poss.within 24 hrs.  718863-001: 500 mg, 10, R190,56  pregn., safety in lactat.not est., concom.St John’s Wort.
       Adults: Herpes zoster: 1 000 mg 3x/dly for 7 days.  718863-002: 500 mg, 30, R571,67  Side effects: Body fat redistribut./accumulat., dizzin., headache, ser.
       Recurr.genit.herpes: 500 mg 2x/day x5 days start.as early as poss.   718863-003: 500 mg, 42, R800,33  CNS/psych.effs., abnorm.co-ordinat., convuls., paraesthes., hypoes-
       Init. within 24 hrs.of S&S onset./dur.prodromal.per.  Dosage: Cannot be used in pts.requir.dos.of less than 500 mg.  thes., neuropathy, GI disturbs., malabsorpt., hepat.fail., myopathy,
       Prevent./suppress.of recurr.H.Simplex: Immunocompet. pts:   Adults:  skin reacts.incl.incr.swell./erythema multiforme/ Stev.John.syndr./
       500 mg once dly. Admin. 250 mg 2x dly.if more than 10 episod.oc-  Herpes zoster: 1 000 mg 3x/dly.x7 days  seborrh./folliculit., nail disords., skin discolourat., pain, alcoh.intol.,
       cur/yr. Immunocomprom.pts: 500 mg 2xdly.  Recurr.genit.herpes: Init within 24 hrs.of S&S onset. 500 mg   allerg. reacts., asthen., hot flush., flu-like sympts., malaise, synco-
       CMV infect.prophylax: Adults & adolesc. 12 yrs. & old: Init.  2x/day x5 days.  pe, aggrav.depress., anx., incr. appet., emot.labilit., impot., confus.,
       ther.as soon as poss.2 000 mg 4xdly post-transpl usual.x90 days.   Prevent.of recurr.H.Simplex: Immunocomprom. pts: 500 mg   hallucinat., imp. coordinat., neuralg., libido chang., speech disords.,
       Poss.extend.in high-risk pts.  2xdly. Immunocompetent pts: 500 mg once dly.  trem., vertigo, tinnit., abnorm.vis., taste pervers., flush., palpitat.,
       Contraindications: Acyclovir hypersens.  CMV infect.& dis.prophylax: Adults & adolesc. from 12 yrs: 2   tachycard., hepatit., weight chang., arthralg./myalg., asthma, si-
       Side effects: Freq: Headache, naus. Less freq: anaem., leucopen.,   000 mg 4xdly x90 days poss.extent.in high risk pts. Init.ther.as early   nusit., URTI, alopec., rais.liv.enzym./ser.cholester.& triglycerid. conc.
       thrombocytopen., neutropen., anaphylax., dizzin., confus., hallucinat.  as poss. post-transpl. Modify dos.accord.to creatin. clear.  Special precautions: Teratogenicity noted, barrier contracept.
       partic.with high dos.for CMV prophylax., lethargy, somnol., decr.con-  Contraindications: Acyclovir hypersens., safety in pregn.& lactat.  in combin.with other methods advis., women of childbear.potent.
       sciousn., agitat., trem., atax., dysarthr., pschot.sympts., convuls.,   not est., no data avail.for childr.,   to undergo pregn. test bef.init.ther., poss.pass.into breast milk,
       encephalopathy, coma, dyspn., abdomin.discomf., vomit., diarrh.,   Side effects: Headache, GI disturbs., skin rash, revers.neurologic.  avoid high fat meal bef.admin., no studies in childr. und.3 yrs or
       hepatit., jaund., abnorm.LFT, skin rash, photosens., prurit., urticar.,   reacts eg confus.& dizzin.in ren. impairm./other predispos.fact., bld.  weigh.&lt;13 kg, not to be used as monother./ add.on as sole agent
       angioed., ren.impairm., ac.ren.fail., fev. Unknown freq: Haemato-  dyscras., ac. hypersens. reacts.incl.anaphylax., psych.disords. incl.  to fail.regim., ref. to prod.lit.when prescrib.other meds., consid.
       logic.changes, accelerat. diffuse hair loss,   aggress.behav.& hallucinat., decr.consciousn., chest pain, tachycard.,   simultan. discont. of all antiretrovir.meds.if combinat. regim.is inter-
       Warnings and special precautions: Thrombot./ thrombocyto-  fac.oed., microangiopath. hypertens., shortn.of breath, wheez., dif-  rupt.because of suspect. intol. & restart medicat.at same time upon
       pen. purpura/haemolyt.uraem.syndr. poss. result.in death report. in   fic.breath., hepatit.with liv.funct.abnormal., erythema multiforme,   resolut. of intol.sympts., intermitt.monother./sequent. reintroduct.
       pts.with advanc. HIV dis./aft.bone marr.& ren.transpl., maint.adeq.   photosens., rash, itch., arthralg., low. back/side pain, ren.insuffic.,   not advis., discont.in sev.rash, if ther. discont. consid.interrupt.ther.
       hydrat., signific.ren.funct.impairm., no data avail.in liv.dis./liv.trans-  decr.freq./amnt of urine, dysmenorrh., fatig., fev.  with other ARV’s to avoid meds.resist.virus develop., consid. an-
       plant, foet.abnormal.report.in rats, concom.meds.compet.with acy-  Special precautions: Concom.meds.compet.with acyclovir for   tihistam. /corticoster.for mild to mod.rash to improv. tol.& resolv.
       clovir for eliminat. potent.incr.plasma lev.of one/both meds., other   eliminat.has potent.to incr.plasma lev. of one/both meds., monit.  rash, prophylax.with appropr. anthistam. bef.init.ther.in childr., be
       concom.meds.aff.ren. physiol., safety in pregn.& lactat.not est., no   ren.funct.with meds. affect. ren.physiology, crosses placenta, act.   alert to psychos.-like reacts.& sev.ac.depress.incl.suicid. ideat./
       data avail.for childr.        metabol. found in breast milk, foet.abnormal. report. in rats, maint.  attempts.report.in pts.with ment.illn./subst. abuse hist., pts.advis.
       Interactions: Cimetidine & probenec.decr. ren.excret./incr.AUC,   adeq.hydrat., ren.funct. impairm., neurolog.reacts.freq.in organ   to alert phys.in case of exper. sev. CNS sympt., liv.dis., monit.liv.
       plasma AUC’s of aciclovir & mycophenolate mofetil both incr.when   transpl. pts. receiv.high dos.for CMV prophylax., no data on high.  enzym. partic. in known/ suspect.hepatit.B/C infect.hist./ concom.
       admin. concom.                dos.in liv.dis./liv.transpl., lact.intol.  hepatotox meds., cholestr./triglycerid. monit.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page319.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page315.html">315</a>&nbsp;&nbsp;&nbsp;<a href="page316.html">316</a>&nbsp;&nbsp;&nbsp;<a href="page317.html">317</a>&nbsp;&nbsp;&nbsp;<a href="page318.html">318</a>&nbsp;&nbsp;&nbsp;<a href="page319.html">319</a>&nbsp;&nbsp;&nbsp;<a href="page320.html">320</a>&nbsp;&nbsp;&nbsp;<a href="page321.html">321</a>&nbsp;&nbsp;&nbsp;<a href="page322.html">322</a>&nbsp;&nbsp;&nbsp;<a href="page323.html">323</a>&nbsp;&nbsp;&nbsp;<a href="page324.html">324</a>&nbsp;&nbsp;&nbsp;<a href="page325.html">325</a>
             </td>
             <td width="35%"><a href="page321.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page321.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
